Mizuho cuts Zscaler stock price target on guidance concerns

Zscaler beat fiscal Q3 expectations with EPS of $1.08 vs. $1.01 consensus and revenue of $850.48 million vs. $835.55 million, while annual recurring revenue grew 25% year over year and gross margin reached 76.6%. However, Mizuho cut its price target to $185 from $210 and flagged weaker fiscal Q4 and fiscal 2027 guidance, alongside uncertainty from recent sales executive departures and new product uptake. The stock remains well positioned in SASE and Zero Trust, but near-term sentiment is tempered by softer forward estimates and multiple analyst target cuts.

Analysis

The key takeaway is not that execution is deteriorating, but that the market is being forced to re-rate Zscaler from a “durable hyper-growth” compounder to a more normal software asset with higher customer concentration risk and weaker visibility into the next leg of growth. When incremental upside is coming from pockets that may not repeat, the multiple compression risk is less about the current quarter and more about the market discounting a lower terminal growth rate over the next 4-8 quarters.

Second-order, the sales-leadership churn matters more than the headline guide cut. In cybersecurity, large platform consolidations often require tightly orchestrated field coverage; turnover can slow large-deal conversion and elongate sales cycles just as competitors push bundled pricing. That creates an opening for larger suite vendors to win share through procurement simplicity, while best-of-breed names can still defend via product depth but may need heavier discounting to do so.

The contrarian view is that the reaction may be partly overdone if the market is extrapolating a guide to a permanent growth deceleration. At this valuation, even modest stabilization in net new ARR or evidence that new products are contributing within 2-3 quarters could trigger a sharp multiple re-expansion. The bigger risk is that the current debate shifts from “can growth remain >20%?” to “is 15-17% the new ceiling?”, and that framing can keep the stock trapped until leadership credibility is rebuilt.

For investors, the setup is better expressed tactically than via outright directional exposure: the stock likely needs either a cleaner channel check or a few quarters of stable execution before it can re-rate sustainably. In the meantime, the name is vulnerable to any evidence that public-sector and APJ are masking weaker core enterprise demand, because those are exactly the segments the market will haircut first once sentiment turns.

Key Decisions for Investors

• Short-term: buy ZS puts or put spreads 1-2 months out into any post-earnings bounce if implied volatility compresses; risk/reward favors fading relief rallies while the market digests the lower forward growth profile.
• Medium-term: pair long PANW / short ZS for 3-6 months to express a “suite wins over best-of-breed under sales turnover” thesis; PANW should benefit if enterprise buyers consolidate vendors and procurement favors breadth.
• If already long ZS, trim into strength and re-enter only after two consecutive quarters of stable or improving organic net new ARR; that’s the clearest signal the growth reset is bottoming.
• For aggressive accounts, consider a small long-dated call spread in ZS only if management shows new-product traction in the next guide cycle; the upside is meaningful if the terminal growth debate stabilizes, but the catalyst window is likely 2-3 quarters.
• Avoid adding on valuation alone: at current levels the stock is cheap only if 16-17% growth proves durable; if growth slips below that band, downside to the multiple remains larger than upside from further earnings beats.